PR Newswire
Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
Aug. 18, 2022
SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- Jemincare, a leading pharmaceutical company from China, announced today that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., have entered into an exclusive worldwide license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Genentech, a member of the Roche Group, for the development and commercialization of its androgen receptor degrader, JMKX002992. Under the terms of the agreement, Genentech will be granted